Nanjing Pharmaceutical Group Company Limited (SHA:600713)
China · Delayed Price · Currency is CNY 5.43
+0.02 (0.37%)
Feb 3, 2026, 3:00 PM CST
SHA:600713 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 53,765 | 53,568 | 53,473 | 50,074 | 44,964 | 39,700 |
Other Revenue | 128.05 | 128.05 | 116.29 | 147.48 | 159.08 | 117.15 |
| 53,893 | 53,696 | 53,590 | 50,222 | 45,123 | 39,817 | |
Revenue Growth (YoY) | -0.16% | 0.20% | 6.71% | 11.30% | 13.33% | 7.16% |
Cost of Revenue | 50,615 | 50,341 | 50,283 | 46,969 | 42,190 | 37,297 |
Gross Profit | 3,278 | 3,355 | 3,307 | 3,252 | 2,934 | 2,520 |
Selling, General & Admin | 1,674 | 1,666 | 1,691 | 1,645 | 1,509 | 1,358 |
Research & Development | 26 | 30.64 | 36.19 | 27.43 | 20.96 | 16 |
Other Operating Expenses | 96.13 | 94.31 | 96.35 | 116.55 | 91.37 | 73.75 |
Operating Expenses | 1,876 | 1,818 | 1,807 | 1,864 | 1,633 | 1,493 |
Operating Income | 1,402 | 1,537 | 1,500 | 1,389 | 1,301 | 1,027 |
Interest Expense | -448.03 | -494.18 | -522.23 | -332.9 | -439 | -363.83 |
Interest & Investment Income | 18.32 | 17.62 | 18.72 | 11.41 | 13.17 | 12.47 |
Other Non Operating Income (Expenses) | -17.9 | -50.1 | -19.42 | -136.95 | -17.44 | -8.08 |
EBT Excluding Unusual Items | 954.44 | 1,011 | 977.09 | 930.24 | 857.44 | 667.98 |
Gain (Loss) on Sale of Investments | 0.9 | - | - | -48.64 | -87.74 | -92.92 |
Gain (Loss) on Sale of Assets | 8.23 | 3.77 | 1.75 | 23.79 | 60.54 | 66.12 |
Asset Writedown | -3.24 | - | - | - | - | - |
Other Unusual Items | -10.94 | -10.94 | -0.77 | 0.63 | 8.63 | 36.62 |
Pretax Income | 949.39 | 1,003 | 978.07 | 906.01 | 838.87 | 677.8 |
Income Tax Expense | 240.32 | 260.28 | 265.26 | 190.09 | 228.31 | 207.76 |
Earnings From Continuing Operations | 709.07 | 743.12 | 712.81 | 715.92 | 610.55 | 470.04 |
Minority Interest in Earnings | -178.35 | -172.49 | -134.98 | -120.25 | -105.37 | -93.62 |
Net Income | 530.72 | 570.63 | 577.83 | 595.67 | 505.18 | 376.41 |
Net Income to Common | 530.72 | 570.63 | 577.83 | 595.67 | 505.18 | 376.41 |
Net Income Growth | -8.40% | -1.25% | -3.00% | 17.91% | 34.21% | 8.50% |
Shares Outstanding (Basic) | 1,301 | 1,303 | 1,298 | 1,254 | 1,042 | 1,043 |
Shares Outstanding (Diluted) | 1,405 | 1,303 | 1,298 | 1,254 | 1,042 | 1,043 |
Shares Change (YoY) | 7.90% | 0.33% | 3.54% | 20.39% | -0.10% | 0.09% |
EPS (Basic) | 0.41 | 0.44 | 0.45 | 0.47 | 0.48 | 0.36 |
EPS (Diluted) | 0.38 | 0.44 | 0.45 | 0.47 | 0.48 | 0.36 |
EPS Growth | -15.11% | -1.57% | -6.32% | -2.06% | 34.35% | 8.41% |
Free Cash Flow | -190.49 | 1,591 | 1,748 | -837.59 | 388.79 | -1,399 |
Free Cash Flow Per Share | -0.14 | 1.22 | 1.35 | -0.67 | 0.37 | -1.34 |
Dividend Per Share | 0.170 | 0.170 | 0.160 | 0.140 | 0.120 | 0.110 |
Dividend Growth | 6.25% | 6.25% | 14.29% | 16.67% | 9.09% | 10.00% |
Gross Margin | 6.08% | 6.25% | 6.17% | 6.48% | 6.50% | 6.33% |
Operating Margin | 2.60% | 2.86% | 2.80% | 2.77% | 2.88% | 2.58% |
Profit Margin | 0.98% | 1.06% | 1.08% | 1.19% | 1.12% | 0.95% |
Free Cash Flow Margin | -0.35% | 2.96% | 3.26% | -1.67% | 0.86% | -3.52% |
EBITDA | 1,526 | 1,674 | 1,654 | 1,543 | 1,448 | 1,163 |
EBITDA Margin | 2.83% | 3.12% | 3.09% | 3.07% | 3.21% | 2.92% |
D&A For EBITDA | 123.6 | 136.53 | 153.76 | 153.84 | 147.27 | 135.81 |
EBIT | 1,402 | 1,537 | 1,500 | 1,389 | 1,301 | 1,027 |
EBIT Margin | 2.60% | 2.86% | 2.80% | 2.77% | 2.88% | 2.58% |
Effective Tax Rate | 25.31% | 25.94% | 27.12% | 20.98% | 27.22% | 30.65% |
Revenue as Reported | 53,893 | 53,696 | 53,590 | 50,222 | 45,123 | 39,817 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.